PIK3CA and cancer: We confirmed that COTI-2 treatment reduced phosphorylated-AKT and -caspase-9 in SHP-77 cells suggesting a role for it negatively modulating the PI3K/AKT/mTOR pathway in cancer cells (Supplementary Figure S1).